Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial.
The cost-effectiveness component of the 18-month CATIE trial of schizophrenia pharmacotherapy (n = 1460) showed that the first-generation antipsychotic perphenazine was US$300-600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Health Policy & Services
- 3801 Applied economics
- 3214 Pharmacology and pharmaceutical sciences
- 1402 Applied Economics
- 1117 Public Health and Health Services
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Health Policy & Services
- 3801 Applied economics
- 3214 Pharmacology and pharmaceutical sciences
- 1402 Applied Economics
- 1117 Public Health and Health Services
- 1115 Pharmacology and Pharmaceutical Sciences